...
机译:高原实体瘤患者的口服丝裂解剂活化蛋白激酶激酶(MEK)抑制剂,WX-554的I期药代动力学和药效学研究
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Newcastle Freeman Hosp Northern Ctr Canc Care Newcastle Upon Tyne NE7 7DN Tyne &
Wear England;
Inst Canc Res Canc Res UK Canc Therapeut Unit London England;
UCB 216 Bath Rd Slough SL1 4EN Berks England;
UCB 216 Bath Rd Slough SL1 4EN Berks England;
WILEX AG Grillparzerstr 18 D-81675 Munich Germany;
WILEX AG Grillparzerstr 18 D-81675 Munich Germany;
WILEX AG Grillparzerstr 18 D-81675 Munich Germany;
Queens Univ Belfast Ctr Canc Res &
Cell Biol Belfast Antrim North Ireland;
Univ Glasgow Beatson West Scotland Canc Ctr Glasgow G12 OYN Lanark Scotland;
Univ Manchester Christie NHS Fdn Trust Manchester M20 4BX Lancs England;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Inst Canc Res Canc Res UK Canc Therapeut Unit London England;
Queens Univ Belfast Ctr Canc Res &
Cell Biol Belfast Antrim North Ireland;
Univ Glasgow Beatson West Scotland Canc Ctr Glasgow G12 OYN Lanark Scotland;
St Jamess Inst Oncol Beckett St Leeds LS9 7TF W Yorkshire England;
Univ Manchester Christie NHS Fdn Trust Manchester M20 4BX Lancs England;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
Newcastle Univ Sch Med Northern Inst Canc Res Paul OGorman Bldg Newcastle Upon Tyne NE2 4HH;
MEK inhibitor; Phase I; Pharmacodynamics; Pharmacokinetics; Optimal biological dose;
机译:晚期实体瘤患者口服促分裂原活化蛋白激酶激酶(MEK)抑制剂WX-554的I期药代动力学和药效学研究
机译:口服丝裂原活化蛋白激酶激酶(MEK)抑制剂曲美替尼联合吉西他滨治疗晚期实体瘤的1b期临床研究
机译:口服小分子促分裂原活化蛋白激酶激酶1/2抑制剂AZD6244(ARRY-142886)在晚期癌症患者中的I期药代动力学和药效学研究。
机译:血管平滑肌细胞氧化应激激活丝裂剂活化蛋白激酶和蛋白激酶B / Akt信号传导:血管病理生理学中的参与
机译:利用荧光光谱研究促分裂原活化蛋白激酶与底物蛋白小分子抑制剂之间的相互作用
机译:口服小分子丝裂原活化的蛋白激酶激酶1/2抑制剂AZD6244(ARRY-142886)在晚期癌症中的I期药代动力学和药效学研究
机译:晚期实体瘤患者口服促分裂原活化蛋白激酶激酶(MEK)抑制剂WX-554的I期药代动力学和药效学研究